Allogeneic hematopoietic stem cell transplantation of patients with FA and high risk features using fludarabine without radiation

Pediatr Blood Cancer. 2009 May;52(5):683-5. doi: 10.1002/pbc.21921.

Abstract

Several factors unique to Fanconi anemia (FA) limit the success of allogeneic hematopoietic stem cell transplantation (HSCT) in this population. In this report, we describe a multi-center pilot study of five consecutive FA patients with high-risk features for transplant prepared with fludarabine, without radiation. Four patients engrafted quickly, experienced minimal toxicity and are well at 43-65 months post-transplant. One patient had a C-mismatched unrelated donor transplant and had unsustained engraftment. This fludarabine based regimen without radiation was safe and effective for four high-risk patients, suggesting that eliminating radiation should be further studied as an approach to HSCT in children with FA.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Fanconi Anemia / surgery*
  • Female
  • Follow-Up Studies
  • Graft Survival / drug effects
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Pilot Projects
  • Radiation
  • Risk Factors
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous
  • Treatment Outcome
  • Vidarabine / analogs & derivatives*
  • Vidarabine / pharmacology

Substances

  • Vidarabine
  • fludarabine